Triazole Compounds as Selective Kv3 Channel Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hearing disorders, such as hearing loss and tinnitus, as well as schizophrenia and epilepsy, lack effective and safe oral medication options that can be administered over a prolonged period, and there is a need for modulators of Kv3 channels that demonstrate channel selectivity and desirable pharmacokinetic parameters.
Innovation Solution
Development of compounds of formula (I), which are small molecule modulators of Kv3 channels, specifically designed to target Kv3.1, Kv3.2, and Kv3.3 channels, offering potential therapeutic benefits for hearing disorders, schizophrenia, epilepsy, and sleep disorders by enhancing or altering channel function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for hearing disorders and CNS conditions are used, then therapeutic effect is achieved, but safety and tolerability for prolonged oral administration deteriorate
Solution Approach 1:
The patent develops novel triazole compounds with modified chemical structures and pharmacokinetic parameters compared to existing treatments. By changing molecular parameters (chemical composition, structure), the compounds achieve therapeutic efficacy while improving safety and tolerability profiles for prolonged oral administration in hearing disorders and CNS conditions
2Measurement precision
If Kv3 channel modulators are developed for hearing disorders and CNS conditions, then channel selectivity is improved, but pharmacokinetic parameters deteriorate
Solution Approach 1:
The patent optimizes the pharmacokinetic parameters (absorption, distribution, metabolism, excretion) of Kv3 channel modulators by modifying chemical structures. This allows the compounds to maintain desired channel selectivity while achieving improved pharmacokinetic profiles suitable for prolonged oral administration
Solution Approach 2:
The patent introduces specific structural modifications at particular positions of the triazole core (substituents on nitrogen and carbon atoms) to achieve local optimization of both channel selectivity and pharmacokinetic properties, allowing different regions of the molecule to contribute differently to overall performance
3Duration of action of stationary object
If existing oral medications are used for prolonged periods, then treatment continuity is maintained, but safety and tolerability deteriorate
Solution Approach 1:
The patent develops novel compounds with improved safety and tolerability parameters that enable prolonged oral administration. By modifying chemical structures and pharmacokinetic properties, the compounds maintain treatment continuity over extended periods without the safety deterioration associated with existing medications
Data Source
AI summary
Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.